Can anyone take Truvada (emtricitabine + tenofovir disoproxil fumarate) for PrEP or HIV treatment, or are there contraindications such as impaired renal function (eGFR < 60 mL/min), severe hypersensitivity, drug interactions, or chronic hepatitis B infection?

No, Not Everyone Can Take Truvada

Truvada (tenofovir disoproxil fumarate/emtricitabine) has specific contraindications and requires careful screening before initiation, particularly for renal function, HIV status, and hepatitis B infection status.

Absolute Contraindications

For PrEP Use

• Unknown or positive HIV-1 status 1: Truvada for PrEP is contraindicated in individuals with HIV infection or unknown HIV status. Using Truvada alone in HIV-positive individuals can lead to drug-resistant HIV variants.
• Estimated creatinine clearance (CrCl) <60 mL/min 1: The FDA label explicitly states that Truvada should not be used for PrEP in HIV-uninfected individuals with CrCl below 60 mL/min.

For HIV Treatment

• CrCl <30 mL/min or hemodialysis 1: Truvada should not be used in HIV-infected patients with severe renal impairment.

Relative Contraindications and Cautions

Renal Disease

Tenofovir disoproxil fumarate-based PrEP is not recommended for individuals with osteopenia or osteoporosis (evidence rating: AIII) or a creatinine clearance rate of less than 60 mL/min (evidence rating: AIIa) 2. The 2016 IAS-USA guidelines are explicit about this threshold for PrEP use.

For HIV treatment in patients with moderate renal impairment (CrCl 30-49 mL/min), dosing must be adjusted to every 48 hours 1.

Bone Disease

• Not recommended for patients with osteopenia or osteoporosis 2: Tenofovir disoproxil fumarate causes decreases in bone mineral density 1.
• For MSM with or at risk for kidney dysfunction, osteopenia, or osteoporosis, daily tenofovir alafenamide/emtricitabine is recommended instead (evidence rating: BIa) 3.

Hepatitis B Coinfection

Truvada should be used with caution in patients with chronic hepatitis B virus infection (evidence rating: BIIa) 2. The critical concern is that severe acute exacerbations of hepatitis B have been reported in patients coinfected with HBV and HIV-1 who discontinue Truvada 1. All patients must be tested for HBV before initiating Truvada, and those with HBV require close monitoring for several months after stopping the medication.

Mandatory Pre-Initiation Screening

Before anyone can take Truvada, the following assessments are required 3:

For PrEP

• Combined HIV antibody and antigen testing (evidence rating: AIa) - must confirm HIV-negative status
• HIV RNA level if clinical suspicion of acute HIV (evidence rating: AIIa) - PrEP should not be initiated if signs or symptoms of acute HIV infection are present unless negative infection status is confirmed
• Serum creatinine level and estimated creatinine clearance (evidence rating: AIIa)
• Hepatitis B surface antigen (evidence rating: AIIa)

Drug Interactions

Do not administer Truvada with other products containing emtricitabine, tenofovir disoproxil fumarate, or lamivudine 1. This includes ATRIPLA, COMPLERA, EMTRIVA, STRIBILD, VIREAD, or lamivudine-containing products. Do not use with HEPSERA (adefovir dipivoxil).

Special Populations Requiring Consideration

Age and Comorbidities

Patients over 50 years, those taking hypertension or diabetes medications, or those with borderline eGFR require more frequent creatinine monitoring (every 3-6 months rather than every 6 months) 2.

Pregnancy and Breastfeeding

While recent data suggest Truvada appears safe during pregnancy and lactation 4, women should not breastfeed while taking Truvada because the drugs pass into breast milk 1.

Common Pitfalls to Avoid

1. Starting PrEP without confirming HIV-negative status: This is the most critical error, as it can lead to drug-resistant HIV 1.

2. Ignoring renal function thresholds: The CrCl <60 mL/min cutoff for PrEP is absolute 1. For HIV treatment, dose adjustment is required at CrCl 30-49 mL/min, and Truvada should not be used below 30 mL/min.

3. Failing to test for hepatitis B: Discontinuing Truvada in HBV-coinfected patients without appropriate monitoring can cause severe hepatitis flares 1.

4. Concurrent nephrotoxic agents: Avoid using Truvada with concurrent or recent use of nephrotoxic drugs (e.g., high-dose or multiple NSAIDs) 1.

5. Inadequate monitoring during use: For PrEP, HIV testing must be repeated at least every 3 months, with creatinine assessment at the first quarterly visit and then at least every 6 months 3.

Clinical Monitoring Requirements

During PrEP Use 3

• At 1 month: Combined HIV antibody and antigen test
• Quarterly: HIV testing, STI screening, creatinine clearance (at first visit then annually), pregnancy testing if applicable
• Every 3-6 months for those at risk for kidney injury: More frequent renal monitoring

If eGFR declines while on PrEP, evaluate potential causes and reassess risks versus benefits of continued use 1.